Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
Editorials & Other Articles
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials [View all]
During the Covid crisis, the Moderna vaccine saved countless lives, but the orange pedophile in the White House and his unqualified brain worm bear killing boy don't believe in a "right to life" for post-fetal beings:
Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials.
As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.
“We do not foresee investing in new phase 3 studies in a foreseeable futures [sic] in vaccines,” Moderna’s CEO Stéphane Bancel told Bloomberg TV, placing emphasis on the word “new.”
When asked if the anti-vaccine climate is going to affect Moderna’s business and ability to develop more vaccines, Bancel said, “100%.”
Currently, the company touts 12 viral or bacterial vaccine programs in phase 2 development or earlier, according to its online pipeline.
When reached for comment, a Moderna spokesperson pointed to the company’s priorities set out in its Nov. 20 earnings release. At the time, the mRNA specialist announced the discontinuation of four clinical mRNA programs and outlined a three-year business strategy with the goal of boosting revenue by 10% in 2026.
“Over the next three years, we expect to build a large seasonal vaccine franchise for at-risk populations and invest the cash generated into oncology and rare disease therapeutics,” Bancel said at the time...
“We do not foresee investing in new phase 3 studies in a foreseeable futures [sic] in vaccines,” Moderna’s CEO Stéphane Bancel told Bloomberg TV, placing emphasis on the word “new.”
When asked if the anti-vaccine climate is going to affect Moderna’s business and ability to develop more vaccines, Bancel said, “100%.”
You cannot make a return on investment if you don't have access to the U.S. market, or because of delays—regulatory-wise—or because your market is much smaller, because you don't have a recommendation by the government,” Bancel said yesterday on the sidelines of the World Economic Forum in Davos, Switzerland.
Currently, the company touts 12 viral or bacterial vaccine programs in phase 2 development or earlier, according to its online pipeline.
When reached for comment, a Moderna spokesperson pointed to the company’s priorities set out in its Nov. 20 earnings release. At the time, the mRNA specialist announced the discontinuation of four clinical mRNA programs and outlined a three-year business strategy with the goal of boosting revenue by 10% in 2026.
“Over the next three years, we expect to build a large seasonal vaccine franchise for at-risk populations and invest the cash generated into oncology and rare disease therapeutics,” Bancel said at the time...
3 replies
= new reply since forum marked as read
= new reply since forum marked as read